• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Correlation with other scales

The AMS scale has been compared with two screening instruments 17: The ADAM scale of Morley et al. 18 and the Screener of Smith et al. 19.  The comparison of the AMS of the two screening instruments for androgen deficiency showed sufficiently good compatibility despite conceptual differences of the scales.

The AMS sufficiently predicted the results of the two screening instruments with high specificity but relatively small sensitivity (see table below).

The values for the prediction of Smith’ screener to ADAM results were similar.

The AMS scale measures a similar phenomenon as the two established screeners for androgen deficiency. This demonstrates again that the AMS scale has a good criterion-oriented validity.

Can the AMS scale be used as a screening instrument for Androgen Deficiency? Results from the collaboration with Prof. Kratzik of Vienna suggest that this is the case if age and BMI are also considered in addition to the AMS results. 17


17. Heinemann LAJ, Saad F, Heinemann K, DoMinh Thai. Can results of the AMS scale predict those of screening scales for androgen deficiency? Aging Male 2004; Submitted for publication.

18. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry III HM. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49:1239-42.

19. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in aging men. Clinical Endocrinology 2000; 53:703-11.

sidebar

Aging Male Symptoms Scale

  • About AMS
  • Self-assessment
  • Languages
  • Development
  • Psychometric Characteristics
  • Correlation with other scales
  • AMS – properties as an outcome measure
  • AMS – properties as a screening tool
  • AMS Publications

To All Diagnostic Tools

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2023 ZEG Berlin

Impressum

Website by Laura Yeffeth.